The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa - Authors' reply.

Minier, Nicolas; Johannessen, Asgeir; Sombié, Roger; Lemoine, Maud; Shimakawa, Yusuke

Minier, Nicolas; Johannessen, Asgeir; Sombié, Roger; Lemoine, Maud; Shimakawa, Yusuke.

Afiliação

Minier N; Institut Pasteur, Université Paris Cité, Unité d'Épidémiologie des Maladies Émergentes, Paris 75015, France.
Johannessen A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Infectious Diseases, Vestfold Hospital, Tønsberg, Norway.
Sombié R; Hepato-Gastroenterology Department, Yalgado Ouédraogo University Hospital Center, Ouagadougou, Burkina Faso.
Lemoine M; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Medical Research Council Unit, London School of Hygiene & Tropical Medicine, Fajara, The Gambia.
Shimakawa Y; Institut Pasteur, Université Paris Cité, Unité d'Épidémiologie des Maladies Émergentes, Paris 75015, France. Electronic address: yusuke.shimakawa@gmail.com.

Lancet Gastroenterol Hepatol ; 9(7): 589-590, 2024 Jul.

Article em En | MEDLINE | ID: mdl-38870961

Assuntos

Antivirais; Hepatite B Crônica; Humanos; Hepatite B Crônica/tratamento farmacológico; Antivirais/uso terapêutico; África/epidemiologia; Definição da Elegibilidade

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite B Crônica Limite: Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google